{"filings":[{"id":1056484,"accession_number":"0001493152-26-028686","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2026-06-15T20:05:40+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience reports Q3 net loss of $624k; CEO Bartlett to retire July 31, Kitchell to succeed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net product sales $506k (+3.5% YoY); net loss $624k vs $580k YoY; EPS ($0.01).","Nine-month net product sales $1.66M (+15.4% YoY); net loss $1.87M vs $2.07M YoY.","CEO Robert Bartlett retiring July 31, 2026; President Jeff Kitchell appointed CEO effective Aug 1.","Director Bernard Blotner leaving board due to health; no replacement named."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":1656000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90552,"accession_number":"0001493152-26-021329","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Pure Bioscience raises $1.0M in private placement at $0.0553/share; directors invest","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of 18,131,096 shares at $0.0553/share for $1.0M gross.","Director Tom Y. Lee invested ~$700,000; director Ivan Chen invested $27,650.","Net proceeds ~$1.0M for R&D, working capital, and general corporate purposes.","Shares sold to accredited investors under Section 4(a)(2)/Reg D exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100160,"accession_number":"0001493152-26-010383","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q2 revenue up 13% to $443K; net loss narrows; USDA cert for PURE Clean","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales Q2 $443K (up 13% YoY); six-month sales $1.15M (up 22% YoY).","Net loss Q2 $785K ($0.01/sh) vs $798K; six-month loss $1.249M vs $1.487M.","Received USDA Biobased Product Certification for new product PURE Clean; expects launch in fiscal Q3.","Partner Bonsai expanding online promotion; exploring biomedical space with Quip Labs; growth in transportation.","In-plant dairy trials at Cal Poly; new marketing campaign targeting dairy farmers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1150000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100159,"accession_number":"0001493152-26-007616","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pure Bioscience shareholders approve increase in authorized shares to 250M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved amendment increasing authorized common shares from 200M to 250M, with 63.87% of outstanding shares voting for.","Elected 7 directors, each receiving over 96% of votes cast.","Ratified Weinberg & Company as auditor for FY 2026 (99.81% approval).","Advisory vote on executive compensation passed with 96.68% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116497,"accession_number":"0001493152-25-027746","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience reports fiscal Q1 2026 revenue up 27% to $707K, net loss narrows to $464K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $707K for Q1 ended Oct 31, 2025, up 27% from $555K YoY.","Net loss $464K vs $689K year ago; net loss per share ($0.00) vs ($0.01).","Adjusted net loss (excl. share-based comp) was $430K vs $632K.","PURE Control now treating leafy greens for commercial sale; traction in transportation with SDC-powered sanitation.","Working with distribution partners in beverage and dairy to roll out membrane treatment solutions."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":707000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116496,"accession_number":"0001493152-25-024276","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"PURE Bioscience promotes Jeff Kitchell to President, Dolana Blount to VP of Operations","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Kitchell appointed President and remains Corporate Secretary, effective Nov 17, 2025.","Robert Bartlett steps down as President but continues as CEO and board member.","Dolana Blount adds VP of Operations to her role as VP Regulatory Affairs.","Both Kitchell (24 yrs) and Blount (27 yrs) are internal promotions from within PURE.","No changes to compensation or other terms disclosed beyond standard officer indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116495,"accession_number":"0001493152-25-020058","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience FY2025 net product sales $2.2M, net loss narrows to $2.4M from $3.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $2,198K for FY2025, up 12.4% from $1,955K in FY2024.","Net loss improved to ($2.4M) from ($3.4M); loss per share ($0.02) vs ($0.03).","Net cash used in operations ($2.0M) vs ($2.5M) in prior year.","Expanded distribution with Hydrite Chemical; launched membrane treatment for dairy/beverage.","Excluding share-based compensation, net loss was ($2.3M) vs ($3.1M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149496,"accession_number":"0001641172-25-015242","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q3 net product sales up 11% YoY; net loss narrows to $580K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $489K in fiscal Q3 ended Apr 30, 2025, up from $440K YoY.","Net loss improved to $580K from $857K in same quarter last year.","Adjusted net loss (excl. share-based comp) was $547K vs $825K YoY.","EPS remained ($0.01) for both quarters; nine-month EPS ($0.02) vs ($0.03) last year.","CEO reports SDC dairy membrane solution now commercial at full-scale dairy plants."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":1435000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168572,"accession_number":"0001493152-25-010568","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q2 net sales up 20% YoY to $391K; net loss narrows to $798K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $391K for fiscal Q2 ended Jan 31, 2025, vs $325K a year ago (+20%).","Net loss $798K vs $1,002K in prior-year quarter; loss per share unchanged at ($0.01).","SG&A expenses fell $194K due to reductions in personnel, professional fees, and stock comp.","Company advanced dairy membrane solutions to full-scale in-plant pilots with a large distribution partner.","Pilot data shows benefits in water/energy savings, fouling removal, and reduced downtime for dairy ops."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":946000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168571,"accession_number":"0001493152-25-003983","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pure Bioscience Announces Results of 2025 Annual Meeting of Stockholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected all seven director nominees with approval ranging from 95.59% to 98.18%.","Ratified Weinberg & Company as independent auditor for fiscal year ending July 31, 2025, with 99.19% approval.","Approved executive compensation on a non-binding advisory basis with 95.49% of votes cast.","61,264,581 shares (54.77% of outstanding) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185682,"accession_number":"0001493152-24-050223","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q1 FY2025 product sales $555K, down 23% YoY; net loss per share ($0.01)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales of $555K for quarter ended Oct 31, 2024, vs $718K YoY, due to budget constraints of a large end-use customer.","Net loss narrowed to $689K from $735K YoY; net loss per share unchanged at ($0.01).","Excluding share-based compensation, net loss was $632K vs $655K YoY.","CEO cites unexpected interruption in product flow to a major customer and lack of replacement revenue as reasons for the decline."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":555000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185681,"accession_number":"0001493152-24-042926","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience reports FY 2024 net loss of $3.4M; product sales up 4.5% to $1.955M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $1.955M in FY 2024 vs $1.871M in FY 2023, up $84K (4.5%).","Net loss improved to ($3.4M) from ($3.9M); net loss per share ($0.03) vs ($0.04).","Net cash used in operations reduced to ($2.5M) from ($3.3M).","Shifted strategy to distribution model; partnered with multiple distributors in fiscal 2024.","R&D focused on Clean-in-Place solutions for food processing equipment sanitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202252,"accession_number":"0001493152-24-037627","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Pure Bioscience secures up to $3M in convertible notes; initial $500k from director Tom Y. Lee","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial tranche of $500,000 convertible promissory note placed with director Tom Y. Lee (affiliates).","Notes bear 7.88% annual interest, mature 3 years; convertible into common at VWAP floor $0.095, cap $0.175.","Company may conduct subsequent closings up to $3.0 million aggregate principal through July 31, 2025.","Conversion triggers include automatic conversion one year after issuance at option of majority holders, and upon corporate transactions.","Offering is exempt from registration under Section 4(a)(2) of the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202251,"accession_number":"0001493152-24-030966","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Pure Bioscience increases authorized common shares from 150M to 200M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved the amendment at the Feb 21, 2024 annual meeting.","Certificate of Amendment filed with Delaware on Aug 5, 2024, effective immediately.","Authorized common stock increased by 50 million shares (33% increase)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218338,"accession_number":"0001493152-24-023859","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q3 net product sales $440K, net loss $857K; loss per share ($0.01)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $440,000 for Q3 FY2024, up 8% vs $406,000 in prior-year quarter.","Net loss $857,000; narrower than $876,000 in Q3 FY2023; net loss per share unchanged ($0.01).","For the nine months ended April 30, 2024, net product sales $1,483,000, net loss $2,594,000.","Company transitioning to distributor model; new Tier Pricing Agreement developed for distributor margins.","Social media platform engagement up 167% in past 90 days; followers up nearly 70%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":1483000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218337,"accession_number":"0001493152-24-018114","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Pure Bioscience appoints Darin Zehr to board of directors, effective May 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Darin Zehr appointed as independent director; will serve on Audit and Compensation Committees.","Zehr is General Manager of Commercial Food Sanitation LLC and has 22 years at Kraft Foods.","Annual cash retainer of $30,000 for board service, payable quarterly on a pro-rata basis.","No family relationships or material interests in transactions requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238273,"accession_number":"0001493152-24-011536","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Pure Bioscience raises $500K via convertible notes from director; up to $3M total","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $500,000 private placement of convertible promissory notes to accredited investors, including board member Tom Y. Lee.","Interest at 7.81% compounded annually; maturity 3 years from issuance.","Conversion price tied to 30-day VWAP, with floor $0.13 and cap $0.21 per share.","Subsequent closings allowed up to $3M aggregate principal through July 31, 2024.","Notes convertible at holder's or company's option; automatic conversion after one year if majority holders elect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238272,"accession_number":"0001493152-24-010300","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q2 net product sales $325K, net loss $1.0M; shifting to distributor model","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $325K in Q2 FY2024, down 18% from $396K YoY; net loss $1.002M vs $1.060M.","Q2 net loss per share ($0.01); six-month net product sales $1.043M, up 21% from $863K.","CEO cites unexpected interruption in product flow to one major customer as cause of revenue shortfall.","Company shifting from direct sales to distributor model to expand market coverage and accelerate growth.","New food segments and dairy/animal health show interest; registered to exhibit at IAFP July 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1043000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238271,"accession_number":"0001493152-24-007825","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pure Bioscience shareholders approve increase in authorized shares to 200M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected with 97-99% of votes cast; terms until next annual meeting.","Ratification of Weinberg & Company as auditor for FY ending July 31, 2024 approved (99.58%).","Non-binding advisory vote on executive compensation passed with 99.14% of votes cast.","2024 Equity Incentive Plan adopted with 99.17% of votes cast.","Amendment to increase authorized common stock from 150M to 200M shares approved with 55.13% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255755,"accession_number":"0001493152-23-044855","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q1 revenue rises 54% to $718K; net loss narrows to $735K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales of $718K for Q1 FY2024, up $251K from $467K in Q1 FY2023.","Net loss improved to $735K from $993K year-over-year; EPS unchanged at ($0.01).","Excluding share-based compensation, net loss was $655K vs $909K.","CEO cites sales initiatives paying off; VP of Sales highlights competitive advantage in food safety.","Business update stresses customer focus, IoT/SaaS innovation, and 100 years of combined staff experience."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":718000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255754,"accession_number":"0001493152-23-038669","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience reports FY2023 net loss of $4.0M, revenue up slightly; Q4 revenue jumps 49% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $1.871M vs $1.813M prior year (+3.2%); net loss widened to $4.0M from $3.5M.","Cash used in operations increased to $3.3M from $2.5M; net loss per share unchanged at ($0.04).","Q4 revenue increased 49% YoY; CEO sees turning point and confirms new customer-driven programs.","Company moving to all-remote work model, closing Rancho Cucamonga facility to reduce costs.","Introduced 'PURE GENIUS' food safety solution at IAFP conference; now in multiple food processing facilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273182,"accession_number":"0001493152-23-024119","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Pure Bioscience raises $1.015M via convertible notes from accredited investors","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued convertible promissory notes for $1.015M initial principal; potential subsequent closings up to $1.8M total.","Notes bear 7.55% annual interest, mature in three years, convertible at 30-day VWAP with $0.15 floor and $0.23 cap.","Board members Tom Y. Lee and Ivan Chen invested $1,000,000 and $15,000 respectively.","Notes sold in private placement under Section 4(a)(2); disinterested board approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290059,"accession_number":"0001493152-23-021231","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q3 net product sales down 18% YoY to $406K; net loss widens to $876K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $406K in Q3 FY2023 vs $497K prior year, down 18% on decreased distribution sales.","Q3 net loss $876K vs $760K prior year; net loss per share flat at ($0.01).","Nine-month net product sales $1.27M vs $1.41M; net loss $2.93M vs $2.26M prior year.","CEO cites key distributor downturn; food division sales partially offset; new sales program initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":1269000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311010,"accession_number":"0001493152-23-008364","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pure Bioscience names Robert Bartlett CEO; Tom Lee resigns, stays on Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tom Y. Lee resigned as President and CEO effective March 15, 2023; will continue on Board.","Robert Bartlett, Board member since Feb 2023, appointed President and CEO; base salary $300k, sign-on $17.5k.","Bartlett granted option to purchase 500k shares, vesting quarterly over one year.","Tom Myers transitioned from COO to EVP Technology and Development; remains on Board.","Kristin A. Taylor resigned from Board effective March 19, 2023; no disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311009,"accession_number":"0001493152-23-008077","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2023-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q2 net loss widens to $1.06M; CEO Tom Y. Lee resigns, Robert Bartlett appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 net product sales $396K, down ~4.6% YoY; net loss $1.06M vs $702K prior year.","Six-month net loss $2.05M vs $1.50M; loss per share ($0.02) unchanged.","CEO Tom Y. Lee resigned March 15; Robert Bartlett named President and CEO.","Tom Myers transitions from COO to EVP Technology & Development for sales and R&D focus.","New CEO says prior sales approach lackluster; plans to refocus on new and existing channels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311008,"accession_number":"0001493152-23-004296","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2023-02-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pure Bioscience shareholders elect seven directors, ratify auditor, approve exec compensation at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected with between 96.60% and 99.19% of votes cast.","Ratification of Weinberg & Company as auditor for FY ending July 31, 2023 approved with 99.87% of votes cast.","Advisory approval of executive compensation passed with 96.84% of votes cast.","Turnout of 59.23% of outstanding shares (65,965,992 of 111,356,485 shares) represented at the meeting.","Broker non-votes totaled 11,742,927 shares on director elections and executive compensation proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329633,"accession_number":"0001493152-22-035436","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q1 FY2023 net product sales $467K, net loss widens to $993K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $467K, down 6% from $497K YoY; net loss $993K vs. $796K.","Net loss per share ($0.01) unchanged; adjusted loss excl. share-based comp $909K vs. $606K.","Adopted by multiple potato processors; eight snack food/bakery facilities; dairy adds six locations with Hydrite.","Hired two regional managers (Midwest, West Coast) to boost street sales."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":467000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329632,"accession_number":"0001493152-22-029839","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2022-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience FY2022 revenue down 51% to $1.8M; net loss widens to $3.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales of $1.81M vs $3.70M in FY2021; royalties fell to $40K from $229K.","Net loss of $3.5M ($0.04/sh) compared to $2.3M ($0.03/sh) in prior year.","Net loss excluding stock compensation was $2.9M; cash used in operations $2.5M.","Sales team expanded: three street execs, Midwest manager, two AVP corporate accounts.","CRM software implemented; two-team sales approach targeting janitorial and sanitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347199,"accession_number":"0001493152-22-019817","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2022-07-19T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"PURE Bioscience raises $3.5M in private placement; CEO and directors participate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $3.5M via private placement of 23,333,332 shares at $0.15/share.","CEO Tom Y. Lee invested $3.26M through affiliates; directors Chen and Rendall invested $93,750 combined.","Proceeds for general corporate purposes including R&D, admin, working capital.","Shares issued under exemption from registration (Section 4(a)(2) and Rule 506).","Disinterested board members approved the transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363611,"accession_number":"0001493152-22-016729","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q3 sales down 11% to $497K; nine-month sales fall 50%; net loss widens","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net product sales $497K (-11% YoY); net loss $760K ($0.01 per share).","Nine-month sales $1.4M (-50% YoY); net loss $2.26M vs $1.59M prior year.","Exclusive distribution deal with Hydrite for dairy/plant-based beverage industries.","Hired VP Sales John Kasperski (ex-Ecolab) and EVP Science Dr. Zhinong Yan (ex-Walmart Food Safety).","PURE Hard Surface disinfectant now shipping to Office Depot and through NIB/GSA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1409000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383407,"accession_number":"0001493152-22-006861","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2022-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q2 sales drop 52% to $415K, net loss $702K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales for Q2 ended Jan 31, 2022 fell 52% to $415K from $868K YoY.","Net loss for Q2 was $702K vs $595K YoY; excluding share-based comp, net loss $522K vs $354K.","Six-month net product sales decreased 60% to $912K from $2.285M; net loss $1.498M vs $775K.","Taylor Farms developing commercial line for SmartWash Boost on leafy greens; LightHouse started production in March 2022.","CEO states SmartWash Boost program set to initiate in Spring 2022; optimistic for revenue increase in upcoming quarters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":912000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383406,"accession_number":"0001493152-22-003505","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2022-02-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pure Bioscience annual meeting: all proposals approved by wide margins","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholder turnout 61.57% (53,613,132 of 87,072,963 shares outstanding).","Five director nominees elected with >96% approval: Tom Y. Lee, Ivan Chen, Tom Myers, Kristin A. Taylor, David M. Rendall.","Ratification of Weinberg & Company as auditor approved with 99.47% of votes cast.","Advisory 'say-on-pay' proposal passed with 88.41% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401212,"accession_number":"0001493152-21-031569","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2021-12-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q1 revenue plunges 65% to $497k; net loss widens to $796k","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $497k, down 65% YoY; net loss $796k vs $180k; EPS $(0.01) vs $(0.00).","Gross margin improved to 65% from 55% due to higher-margin product mix.","Hired marketing firm; interviewing for Director of Sales; negotiating Canadian distributor contract.","In-facility validation with second largest US produce processor; evaluating at 16-plant food processor chain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":497000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401211,"accession_number":"0001493152-21-026622","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience reports FY2021 net loss of $2.3M; product sales drop 47% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $3.698M, down 47% from $6.917M in FY2020.","Net loss of $2.3M vs net income of $4K in prior year; diluted loss per share $(0.03).","Gross margin fell to 50% from 58% due to product mix shift.","Cash used in operations $1.2M vs cash provided $669K in prior year.","Business updates: ongoing work with Taylor Farms, new adoption by citrus packer and indoor farming firm, new sales hire."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420146,"accession_number":"0001493152-21-020997","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2021-08-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pure Bioscience appoints Ivan Chen as Board Chair, replacing Tom Lee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ivan Chen, current non-employee director, appointed Board Chair effective August 19, 2021.","Tom Lee steps down as Chair but remains President and Chief Executive Officer.","No other changes to the Board or management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}